Clinical Oncology
Volume 22, Issue 2 , Pages 131-135 , March 2010

Radioiodine Ablation for Differentiated Thyroid Cancer—None, One Dose or Two?

  • G.J.G. Rees

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: G.J.G. Rees, Cancer Unit, Royal United Hospital, Combe Park, Bath BA1 3NG, UK. Tel: +44-7812-178901; Fax: +44-117-3179715.

Received 28 August 2009 ,Revised 12 October 2009 ,Accepted 10 November 2009.

References 

  1. British Thyroid Association, Royal College of Physicians . Guidelines for the management of thyroid cancer, 2nd edn. Report of the thyroid cancer guidelines update group. London: Royal College of Physicians; 2007;
  2. British Thyroid Association, Royal College of Physicians . Guidelines for the management of thyroid cancer in adults. London: Royal College of Physicians; 2002;
  3. Gerrard G, Gill V. Thyroid cancer guidelines – what's new?. Clin Oncol. 2008;20:264–266
  4. Cobin RH, Gharib H, Bergman DA, et al. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract. 2001;7:202–220
  5. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:1–33
  6. Pacini F, Schlumberger M, Harmer C, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol. 2005;153:651–659
  7. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803
  8. Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–1959
  9. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–428
  10. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab. 1992;75:714–720
  11. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668–3676
  12. Creutzig H. High or low dose radioiodine ablation of thyroid remnants?. Eur J Nucl Med. 1987;12:500–512
  13. Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073MBq and 3700MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med. 1991;32:252–254
  14. Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab. 2004;89:1666–1673
  15. Maenpaa HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS ONE. 2008;3:e1885
  16. Kukulska A, Krajewska J, Roskosz J, et al. Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100mCi versus 60mCi. Endokrynol Pol. 2006;57:374–379
  17. Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986;63:960–967
  18. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937–941
  19. Maxon HR. Detection of residual and recurrent thyroid cancer by radionuclide imaging. Thyroid. 1999;9:443–446
  20. Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S. An analysis of ‘ablation of thyroid remnants’ with I-131 in 511 patients from 1947–1984: experience at University of Michigan. J Nucl Med. 1984;25:1287–1293
  21. Robbins RJ, Schlumberger MJ. The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med. 2005;46:28S–37S
  22. Doi SA, Woodhouse NJ, Thalib L, Onitilo A. Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited. Clin Med Res. 2007;5:87–90
  23. Mazzaferri E. A randomized trial of remnant ablation – in search of an impossible dream?. J Clin Endocrinol Metab. 2004;89:3662–3664
  24. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004;150:105–112
  25. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer. 2007;110:1451–1456
  26. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–953
  27. Hay ID, Bergstrahl EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–1057
  28. Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr Pract. 2007;13:498–512
  29. Verburg FA, Dietlein M, Lassmann M, Luster M, Reiners C. Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:343–346
  30. Tuttle RM, Fagin JA. Can risk-adapted treatment recommendations replace the one size fits all approach for early-stage thyroid cancer patients?. Oncology. 2009;23:1–4
  31. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89:1638–1644
  32. Sandeep TC, Strachan MW, Reynolds RM, et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab. 2006;91:1819–1825
  33. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:504–515
  34. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879–885
  35. McHenry C, Jarosz H, Davis M, Barbato AL, Lawrence AM, Paloyan E. Selective postoperative radioactive iodine treatment of thyroid carcinoma. Br J Surg. 1990;77:110–113
  36. Hay ID, McDougall IR, Sisson JC. Perspective: the case against radioiodine remnant ablation in patients with well-differentiated thyroid carcinoma. J Nucl Med. 2008;49:1395–1399
  37. Morris DM, Boyle PJ, Stidley CA, Altobelli KK, Parnell T, Key C. Localized well-differentiated thyroid carcinoma: survival analysis of prognostic factors and (131) I therapy. Ann Surg Oncol. 1998;5:329–337
  38. Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:457–480
  39. Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med. 1998;129:622–627
  40. Kloos R, Mazzaferri E. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab. 2005;90:5047–5057
  41. Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol. 2007;19:83–86
  42. Wong JB, Kaplan MM, Meyer KB, Pauker SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin North Am. 1990;19:741–760
  43. Dragoiescu C, Hoekstra OS, Kuik DJ, et al. Feasibility of a randomized trial on adjuvant radio-iodine therapy in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2003;58:451–455

PII: S0936-6555(09)00375-6

doi: 10.1016/j.clon.2009.11.005

Clinical Oncology
Volume 22, Issue 2 , Pages 131-135 , March 2010

Article Tools